Christine Bulawa received a PhD in Biochemistry from the University of Wisconsin-Madison and was a postdoctoral fellow at the Massachusetts Institute of Technology. At Millenium Pharmaceuticals, Dr. Bulawa developed methods for target validation for the human pathogen Candida albicans that became a cornerstone of a partnership with Pfizer in the area of antifungal drug discovery. As part of this program, Dr. Bulawa’s research team developed genomic technologies such as mRNA arrays and successfully applied these to discover compound mechanism-of-action. In addition, Dr. Bulawa used yeast as a model system to advance targets and compounds in Millennium's Cardiovascular Biology, Metabolic Disease, Inflammation, and Oncology programs. At FoldRx Pharmaceuticals, Dr. Bulawa established a discovery program for Parkinson’s disease based on the misfolding, aggregation, and toxicity of the clinically relevant protein alpha-synuclein and developed novel assays applicable to protein trafficking diseases, such as Cystic Fibrosis, in which misfolded proteins fail to be transported to the correct cellular location.